55402com永利-(中國)ios/Android版|百度百科

师资

EN       返回上一级       师资搜索
张健
教授
百千万人才工程国家级人选
0755-88018036
zhangjian@sustech.edu.cn

主要学术成绩简介

张健,55402com永利医学院教授,55402com永利-伦敦国王学院医学院副院长,致诚书院院长,博士生导师,“百千万人才工程”国家级人选,国务院特贴专家,深圳市引进国家级领军人才。2011年创建华南地区首家转化医学研究中心并任主任,曾创建和担任“长寿与老年相关疾病研究”教育部重点实验室主任、学术委员会副主任。目前担任中国生物技术学会转化医学分会副主任委员,广东省细胞微环境与疾病研究重点实验室学术委员会委员,中国抗癌协会肿瘤转移专业委员会常务委员,深圳市生物医药促进会副会长,中国肿瘤防治联盟深圳市联盟副主席,2015-2017《Medical Oncology》副主编。SCI 发表文章总数120余篇。 博士毕业于美国密歇根大学医学院,2004 年起任美国国防部(DOD)医学课题评审委员,从2009 年起任我国教育部特聘专家和国家自然科学基金杰青、国合、重点、面上等项目评审专家。2013 年被选为“全国优秀科技工作者”,2014 年入选“国家百千万人才工程”和“国家有突出贡献中青年专家”。2016年获批深圳市引进国家级领军人才(A类),负责筹备和成功创建55402com永利医学院临床医学和生物医学科学本科专业。研究方向:肿瘤免疫微环境异质性与肿瘤耐药和转移;衰老与肿瘤。

 

研究领域

肿瘤转化医学研究

肿瘤耐药、复发与转移

衰老与肿瘤

 

教育经历

1981-1986: 学士,天津医科大学临床医学系

1997-1998: 硕士,Old Dominion University & East Virginia Medical School 免疫学专业

1998-2001: 博士, University of Michigan 病理学专业

 

主要工作经历

1986.8-1995.1  天津市第三医院/天津市老年医学研究所,内科住院医师、主治医师

1995.1-1996.8   美国威斯康星-麦迪逊大学老年医学研究所 世界卫生组织奖学金访问学者

1996.8-1998.8  东弗吉尼亚医学院老年医学研究中心Visiting Research Scientist

1998.8-2004.6    美国密歇根大学医学院博士在学/研究员

2004.7-2010.12   美国匹兹堡大学和密歇根大学医学院助理教授 (Tenure track)

2011.1-2016. 7   长寿与老年相关疾病省部共建教育部重点实验室/广西医科大学转化医学院就中心主任/教授

2016.3-             美国匹兹堡大学医学院兼职教授

2016.7-             55402com永利医学院教授

 

荣誉

2019-深圳市生物医药促进会副会长

2018-中国肿瘤防治联盟深圳市联盟副主席

2014-获得国务院政府特殊津贴专家

2013-入选国家百千万人才工程国家级人选并获“有突出贡献的中青年专家”荣誉称号

2013-美国基础泌尿研究学会(SBUR)颁发的International lecturer证书

2012-全国优秀科技工作者

2011-广西壮族自治区八桂学者、广西壮族自治区政府参事

2007-Mentoring Dr. Yi Lu, Young Investigator Travel Award, ASBMR

2005-Mentoring Dr. Yi Lu, Scholar-in-Training Award, AACR

2003-Scholar-in-Training Award, AACR

2003- Plenary Poster Award of 25th Annual Meeting of American Society for Bone and Mineral Research

2002-Alice L. Jee Memorial Young Investigator Award

2000-Plenary Poster Award of 22nd Annual Meeting of American Society for Bone and Mineral Research

1994- Fellowship Award, World Health Organization (WHO)

 

代表著作

  1. Zhang J, Dai J, Qi Y, Lin D, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 107:1235-1244, 2001.

  2. Zhang J, Johnston G, Stebler B, Keller ET. Oxidative stress-mediated activation of NFkB and the interleukin-6 promoter requires NFkB-inducing kinase activity. Antioxidant & Redox Signaling. 3:493-504, 2001.

  3. Zhang J, Dai J, Lin D, Habib P, Smith P, Murtha J, Fu Z, Yao Z, Qi Y, Keller ET. Osteoprotegerin abrogates chronic alcohol ingestion-induced bone loss in mice. J Bone Miner Res 17:1256-1263, 2002.

  4. Zhang J, J Dai, Yao Z, Lu Y, Dougall W, Keller ET. Soluble RANK-Fc diminishes prostate tumor progression in bone. Cancer Res. 63:7883-90, 2003

  5. Zhang J, Lu Y, Kitazawa R, Kitazawa S, Dai J, Qi W, Zhao X, Yao Z, Hall D, Keller ET. Bioluminescence imaging of RANK ligand transcriptional regulation in vivo. Prostate. 59:360-9, 2004

  6. Zhang J, Dai J, Lu Y, Yao Z, O’Brein C, Qi W, Hall D, Ershler WB, Keller ET. In vivo visualization of aging-associated gene transcription: evidence for free radical theory of aging. Experimental Gerontology. 39:239-247, 2004

  7. Lu Y, Cai Z, Galson DL, Xiao G, Liu YL, George D, Melhem MF, Yao Z and Zhang J*. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 66:1311-8, 2006

  8. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J*. Monocyte chemotactic protein-1 (MCP-1) mediates prostate cancer-induced bone resorption. Cancer Res, 67:3646-53, 2007

  9. Lu Y, Cai Z, Xiao G, Liu Y, Keller ET, Yao Z, and Zhang J*.   CCR2 expression correlates with prostate cancer progression. J Cell Biochem. 101:676-685, 2007

  10. Lu Y, Yao Z, and Zhang J*. Prostate cancer bone metastasis: interaction between tumor cells and bone microenvironment. Chin J of Biochem and Molecul Biol, 23(3):167-171, 2007

  11. Lu Y, Xiao G, Galson DL, Nishio Y, Mizokami A, Yao Z, and Zhang J*. PTHrP-induced MCP-1 production by human bone marrow endothelial cells promotes osteosteoclastast differentiation and prostate cancer cell proliferation and invasion in vitro.   Int J of Cancer. 121:724-733, 2007

  12. Lu Y, Nie DB, Witt WT, Chen Q, Shen M, Xie H, Lai L, Dai Y, Zhang J*. Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3β phosphorylation. Mol Cancer Therapeutics, 7(10):3203-11, 2008

  13. Lu Y, Wang J, Xu Y, Koch AE., Cai Z, Chen X, Galson DL, Taichman RS, and Zhang J*. CXCL16 functions as a novel chemotactic factor for prostate cancer cells in vitro. Mol Cancer Res, 6(4): 546-54, 2008

  14. Lu Y, Chen QY, Corey E, Xie W, Fan J, Dai J, Mizokami A, and Zhang J*. Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone. Clin Exp Metastasis, 26(2):161-9, 2009

  15. Cai Z, Chen QY, Chen J, Lu Y, Xiao GZ, and Zhang J*. MCP-1 promotes lung cancer-induced bone resorptive lesions in vivo. Neoplasia, 11(3):228-236, 2009

  16. Zhang J, Patel L, and Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21(1):41-8, 2010

  17. Zhang J, Lu Y, and Pienta KJ. Multiple roles of CC chemokine ligand 2 (CCL2) in promoting prostate cancer growth. J Natl Cancer Inst. 102(8):522-8, 2010

  18. Zhang J*, Sud S, Mizutani K, Gyetko MR, and Pienta KJ. Activation of urokinase plasminogen activator (uPA) and its receptor (uPAR) axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 2011

  19. Zhang J, Patel L, Pienta KJ. Targeting Chemokine (C-C motif) Ligand 2 (CCL2) as an Example of Translation of Cancer Molecular Biology to the Clinic. Progress in Molecular Biolology: Translational Sciences. 2010;95:31-53.

  20. Guo H, Yun C, Hou G, Du J, Huang X, Lu Y, Keller ET, Zhang J*, Deng J*,Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. Plos One. 9(6):e100394, 2014

  21. Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J*. Targeting Notch Signaling Pathway in Cancer Therapeutics. Thoracic Cancer, 2014, 5; 473-86

  22. Hongwei Guo, Xiaolin Zhou, Yi Lu, Liye Xie, Qian Chen, Evan T. Keller, Qian Liu, Qinghua Zhou* , and Zhang J*. Translational progress on tumor biomarkers. Thoracic Cancer. 27 JUL 2015, DOI: 10.1111/1759-7714.12294

  23. Yu Zhu, Chunlin Zou, Zhe Zhang, Chaonan Qian, Xin Yang, Junlin Shi, Yudui Xia,  Zhang J*, Yi Lu*. MEK inhibitor diminishes nasopharyngeal carcinoma (NPC) cell growth and NPC-induced osteoclastogenesis via modulating CCL2 and CXCL16 expression. Tumor Biology, 2015, 36(11):8811-8.

  24. Sha He, Yi Lu, Xia Liu, Xin Huang, Evan Keller, Chao-Nan Qian* Zhang J*; Wnt3a: function and implication in cancer. Chinese Journal of Cancer, 2015, 34(3):50.

  25. Lihui Wang, Yanli He, Weijun Liu, Shengbin Bai, Lei Xiao, Jie Zhang, Saravana M. Dhanasekaran, Zhuwen Wang, Shanker Kalyana-Sundaram, O. Alejandro Balbin, Sudhanshu Shukla, Yi Lu, Jules Lin, Rishindra M. Reddy, Philip W. Carrott, Jr., William R. Lynch, Andrew C. Chang, Arul M. Chinnaiyan, David G. Beer*, Zhang J*, Guoan Chen*. Non-coding RNA LINC00535 promotes lung adenocarcinoma progression via the Akt pathway. Oncotarget, 7(10):11487-99, 2016.

  26. Jing Li, Xin Yang, Hao Guan, Atsushi Mizokami, Evan T. Keller, Xiaozhen Xu, Xia Liu, Jiyong Tan, Longyuan Hu, Yi Lu*, Zhang J*. Exosome-derived microRNAs contribute to prostate cancer chemoresistance. International Journal of Oncology, 2016, 49:838-846.

  27. Yeguo Yang, Yi Lu, Lihui Wang, Atsushi Mizokami, Evan T. Keller, Zhang J*, Jiejun Fu*. Skp2 inhibition attenuates the resistance of prostate cancer cells to paclitaxel by up-regulation of p27. Oncology Reports, 2016, 36:559-566.

  28. Yang Liu, Yi Chai, Zhang J*, and Junwei Tang*. A function variant at miR-501 alters susceptibility thepatocellular carcinoma in a Chinese han population. Cell Physiol Biochem, 38(6):2500-8, 2016.

  29. Qiuyan Chen, Siyuan Qin, Yang Liu, Minghuang Hong, Chao-Nan Qian, Evan T Keller, Zhang J, Lu Y*. IGFBP-6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget, 2016, Oct 18;7(42):68140-68150.

  30. Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang* and Lu Y*. Metformin targets multiple signaling pathways in cancer. Chinese Journal of Cancer, 2017; 36(1):17.

  31. Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D*, Deng J*, and Zhang J*. Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling. Sci Rep. 2017; 7: 41656.

  32. Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T. Keller, Yi Lu* and Jian Zhang*. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chinese Journal of Cancer, 2017; 36:35

  33. Yutao Gao, Xia Liu, Ting Li, Luwei Wei, Antai Yang, Yi Lu, Jian Zhang, Li Li, Sumei Wang and Fuqiang Yin. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncology Reports. 2017

  34. Jinlu Dai, Yi Lu, Hernan Roca, Jill M. Keller, Jian Zhang, Laurie K. McCauley and Evan T. Keller. Immune mediators in the tumor microenvironment of prostate cancer. Chinese Journal of Cancer, 2017; 36:29